A retrospective, multicentre study assessing combination of Denosumab and immune checkpoint inhibition in patients with metastatic melanoma and bone metastases
Latest Information Update: 23 Jul 2019
At a glance
- Drugs Denosumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Bone metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Jul 2019 New trial record
- 01 Jul 2019 Results published in the Cancer Immunology Immunotherapy